Re: Adjuvant Weekly Docetaxel for Patients with High Risk Prostate Cancer after Radical Prostatectomy: A Multi-institutional Pilot Study
European Urology. 2007;52(5):1530-1531 
Re: Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis
European Urology. 2018;74(1):121-122
Cause-specific mortality following radical prostatectomy
Prostate Cancer and Prostatic Diseases. 2011;15(1):106-110
Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients
Prostate Cancer and Prostatic Diseases. 2014;18(1):31-37
Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer?
BJU International. 2010;106(11):1596-1600
Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
Yearbook of Urology. 2006;2006:201-202
Re: Predicting Prostate Cancer-specific Outcome After Radical Prostatectomy Among Men with Very High-risk cT3b/4 PCa: A Multi-institutional Outcome Study of 266 Patients
European Urology. 2016;70(3):541-542
Reply to Michael Froehner's Letter to the Editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. Eur Urol 2013;64:372–8
European Urology. 2014;65(3):e42
Re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. Eur Urol 2013;64:372–8
European Urology. 2014;65(3):e41
Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer
Cancer. 2018;124(7):1391-1399